Loxo Oncology, Inc
LOXO
LOXO was delisted on the 14th of February, 2019.
129 hedge funds and large institutions have $2.4B invested in Loxo Oncology, Inc in 2017 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 49 increasing their positions, 24 reducing their positions, and 4 closing their positions.
1,075% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 4
267% more funds holding in top 10
Funds holding in top 10: 3 → 11 (+8)
113% more capital invested
Capital invested by funds: $1.12B → $2.4B (+$1.27B)
104% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 24
50% more funds holding
Funds holding: 86 → 129 (+43)
63% less call options, than puts
Call options by funds: $2.09M | Put options by funds: $5.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$36.5M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$32.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$26.2M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$23.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$20.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$29.5M |
| 2 |
DM
Deerfield Management
New York
|
-$27.8M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$13.9M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$13.4M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$12.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
126
Prelude Capital Management
New York
| $22K | +$15K | +270 | New |
|
127
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $16K | +$11.1K | +200 | New |
|
|
MAM
128
Meeder Asset Management
Dublin,
Ohio
| $5K | – | – | – |
|
129
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | -$23.1K | -417 | -92% |
|
|
RCM
130
RA Capital Management
Boston,
Massachusetts
| – | -$12.6M | -298,935 | Closed |
|
|
AG
131
Artal Group
Luxembourg
| – | -$2.73M | -65,000 | Closed |
|
|
SCA
132
Secor Capital Advisors
New York
| – | -$1.33M | -31,689 | Closed |
|
133
D.E. Shaw & Co
New York
| – | -$818K | -19,434 | Closed |
|
LOXO Hedge Fund Activity: Q2 2017 in Review
129 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q2 2017, worth a combined $2.4B — up 113% from $1.12B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new LOXO positions and 4 closed out — a net gain of 43 holders — while 49 added to existing stakes and 24 trimmed.
The largest buyer was OppenheimerFunds, opening a new position worth an estimated $36.5M. The largest seller was Victory Capital Management, cutting an estimated $29.5M.
- 129 institutional investors held Loxo Oncology, Inc (LOXO) as of Q2 2017, up from 86 in Q1 2017.
- Funds reported $2.4B of Loxo Oncology, Inc stock for Q2 2017, up 113% quarter-over-quarter.
- 47 funds opened new Loxo Oncology, Inc positions in Q2 2017 and 4 closed out, a net change of +43 holders.
- The largest Loxo Oncology, Inc buyer in Q2 2017 was OppenheimerFunds, an estimated $36.5M added.
- The largest Loxo Oncology, Inc seller in Q2 2017 was Victory Capital Management, an estimated $29.5M sold.
Based on aggregated 13F filings for Q2 2017.